Galectin Therapeutics is working to improve the lives of patients with MASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in MASH cirrhosis.
News
-
03/31/26
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update -
03/17/26
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. -
02/26/26
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (MASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More